Novo to market ‘connected’ insulin pens next year

Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.

The Danish pharma is trying to stay ahead of Eli Lilly and Sanofi in an increasingly competitive insulin market, particularly in the US where the pressure is on to justify the value of products.